RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB

被引：4
|
作者：
Kaur, P. [1 ]
Chow, V. [1 ]
Zhang, N. [1 ]
Markus, R. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.4763
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0167
引用
收藏
页码：714 / 714
页数：1
相关论文
共 50 条
  • [31] A simple and cost-effective assay for measuring anti-drug antibody in human patients treated with Adalimumab
    Li, Maohua
    Li, Hongzhen
    Gao, Kai
    Wang, Muyang
    An, Wenqi
    Zhu, Yaran
    Ding, Li
    Wang, Lan
    Gu, Jingliang
    Zuo, Gonglin
    Sun, Le
    JOURNAL OF IMMUNOLOGICAL METHODS, 2018, 452 : 6 - 11
  • [32] The effect of total and free anti-drug antibodies on infliximab pharmacokinetics between 2 drug administrations
    Roque Ramos, L.
    Barosa, R.
    Nunes, A.
    Regalado, A.
    Vieira, A.
    Freitas, J.
    Demengeot, J.
    Garces, S.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S377 - S377
  • [33] IgG-Enzyme Fusion Protein: Pharmacokinetics and Anti-Drug Antibody Response in Rhesus Monkeys
    Boado, Ruben J.
    Hui, Eric Ka-Wai
    Lu, Jeff Zhiqiang
    Pardridge, William M.
    BIOCONJUGATE CHEMISTRY, 2013, 24 (01) : 97 - 104
  • [34] Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
    Vallejos, Chelsea
    Cooper, Jennifer
    Pan, Ingrid
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 705 - 707
  • [35] Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels
    Ruiz-Argueello, Begona
    del Agua, Ainhoa Ruiz
    Torres, Nerea
    Monasterio, Alberto
    Martinez, Antonio
    Nagore, Daniel
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (12) : E287 - E289
  • [36] REAL-LIFE INFLIXIMAB AND ADALIMUMAB TROUGH LEVEL AND ANTI-DRUG ANTIBODY MEASUREMENTS IN RHEUMATOLOGY: THE FINNISH EXPERIENCE
    Ho, D.
    Valtanen, S.
    Havana, M.
    Kroger, L.
    Eklund, K.
    Jokiranta, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 827 - 827
  • [37] Evaluating the relationship between infusion-related reactions and anti-drug antibody status: Results from 111 patients with Fabry disease treated with pegunigalsidase alfa
    Hopkina, Robert J.
    Hughesb, Derralynn
    Bernatc, John A.
    Linhartd, Ales
    Longoe, Nicola
    Tondelf, Camilla
    Vujkovacg, Bojan
    Pisanih, Antonio
    Knolli, Jasmine
    Koulinskaj, Irene
    Piottij, Giovanni
    Chertkoffk, Raul
    Alonk, Sari
    Sakovl, Anat
    Wallacem, Eric L.
    MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02)
  • [38] METHOD COMPARISON STUDY OF ASSAYS FOR THE DETERMINATION OF INFLIXIMAB, ADALIMUMAB, AND ANTI-DRUG ANTIBODY LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
    Nagore, D.
    Ruiz del Agua, A.
    Pascual, J.
    Llinares-Tello, F.
    Herreros, B.
    Martinez, A.
    Martin, S.
    Navarro, R.
    del Rio, L.
    GUT, 2015, 64 : A99 - A100
  • [39] Factors associated with anti-drug antibody production in ankylosing spondylitis patients treated with the infliximab biosimilar CT-P13
    Kim, Yongbum
    Choi, Nayeon
    Shin, Ji-Hui
    Jo, Sungsin
    Nam, Bora
    Kim, Tae-Hwan
    JOURNAL OF RHEUMATIC DISEASES, 2025, 32 (02): : 136 - 144
  • [40] The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice
    Brunn, Nicholas D.
    Mauze, Smita
    Gu, Danling
    Wiswell, Derek
    Ueda, Roanna
    Hodges, Douglas
    Beebe, Amy M.
    Zhang, Shuli
    Escandon, Enrique
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 356 (03): : 574 - 586
12345